Cargando…
The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma
Patient-derived preclinical models are now a core component of cancer research and have the ability to drastically improve the predictive power of preclinical therapeutic studies. However, their development and maintenance can be challenging, time consuming, and expensive. For neuroblastoma, a devel...
Autores principales: | Tucker, Elizabeth R., George, Sally, Angelini, Paola, Bruna, Alejandra, Chesler, Louis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065808/ https://www.ncbi.nlm.nih.gov/pubmed/33808071 http://dx.doi.org/10.3390/jpm11040248 |
Ejemplares similares
-
Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy
por: Kamili, Alvin, et al.
Publicado: (2020) -
The Promise and the Hype of ‘Personalised Medicine’
por: Maughan, Tim
Publicado: (2017) -
Personalised Medicine and the Economy of Biotechnological Promise
por: Sturdy, Steve
Publicado: (2017) -
Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019) -
What is the promise of personalised nutrition?
por: Ferrario, Paola G., et al.
Publicado: (2021)